Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul Kluetz

Showing results (11-20 of 35) with videos related to

Pageof 4
Sort By:
Clinical Pharmacology and Therapeutics|July 30, 2019
Using a Benefit-Risk Analysis Approach to Capture Regulatory Decision Making: Renal Cell CarcinomaG K Raju, Karthik Gurumurthi, Reuben Domike, et al.
Frontiers in Oncology|November 4, 2015
Successes and Challenges of PARP Inhibitors in Cancer TherapyTiffany K Ricks, Haw-Jyh Chiu, Gwynn Ison, et al.
The Lancet. Oncology|April 17, 2025
Use of patient-reported outcomes to inform symptom and functional outcomes in cancer drug regulatory decisions: challenges and future directionsFrancesco Pignatti, Peter Mol, Chantal Quinten, et al.
Journal of the National Cancer Institute|August 8, 2018
Overview of Oncology and Hematology Drug Approvals at US Food and Drug Administration Between 2008 and 2016Jiaxi Zhou, Jonathon Vallejo, Paul Kluetz, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|October 10, 2024
Most Common Symptomatic Adverse Reactions of Cancer Treatments From US Drug Labels (2015-2021) to Inform Selection of Patient-Reported OutcomesErica G Horodniceanu, Tejaswi Datla, Meena N Murugappan, et al.
The Oncologist|October 9, 2015
U.S. Food and Drug Administration Approval Summary: Ramucirumab for the Treatment of Metastatic Non-Small Cell Lung Cancer Following Disease Progression On or After Platinum-Based ChemotherapyErin Larkins, Barbara Scepura, Gideon M Blumenthal, et al.
JAMA Oncology|October 16, 2015
Benefit-Risk Summary of Nivolumab for Patients With Metastatic Squamous Cell Lung Cancer After Platinum-Based Chemotherapy: A Report From the US Food and Drug AdministrationDickran Kazandjian, Sean Khozin, Gideon Blumenthal, et al.
JCO Oncology Practice|November 12, 2024
Administrative Aspects of Molecular Diagnostics-Oversight, Regulatory Approval Process, Clinical and Operational Workflows, and Payment ModelsLalan Wilfong, Lauren Baggett, Philip Reena, et al.
Cancer Discovery|December 2, 2022
Highlights of FDA Oncology Approvals in 2022: Tissue-Agnostic Indications, Dosage Optimization, and Diversity in Drug DevelopmentElizabeth S Duke, Michael J Fusco, Patrick DeMoss, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|April 2, 2022
US Food and Drug Administration Analysis of Patient-Reported Diarrhea and Its Impact on Function and Quality of Life in Patients Receiving Treatment for Breast CancerTing-Yu Chen, Bellinda L King-Kallimanis, Lyna Merzoug, et al.
Pageof 4

Showing results (11-20 of 35) with videos related to

Sort By:
Pageof 4
Clinical Pharmacology and Therapeutics|July 30, 2019
Using a Benefit-Risk Analysis Approach to Capture Regulatory Decision Making: Renal Cell CarcinomaG K Raju, Karthik Gurumurthi, Reuben Domike, et al.
Frontiers in Oncology|November 4, 2015
Successes and Challenges of PARP Inhibitors in Cancer TherapyTiffany K Ricks, Haw-Jyh Chiu, Gwynn Ison, et al.
The Lancet. Oncology|April 17, 2025
Use of patient-reported outcomes to inform symptom and functional outcomes in cancer drug regulatory decisions: challenges and future directionsFrancesco Pignatti, Peter Mol, Chantal Quinten, et al.
Journal of the National Cancer Institute|August 8, 2018
Overview of Oncology and Hematology Drug Approvals at US Food and Drug Administration Between 2008 and 2016Jiaxi Zhou, Jonathon Vallejo, Paul Kluetz, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|October 10, 2024
Most Common Symptomatic Adverse Reactions of Cancer Treatments From US Drug Labels (2015-2021) to Inform Selection of Patient-Reported OutcomesErica G Horodniceanu, Tejaswi Datla, Meena N Murugappan, et al.
The Oncologist|October 9, 2015
U.S. Food and Drug Administration Approval Summary: Ramucirumab for the Treatment of Metastatic Non-Small Cell Lung Cancer Following Disease Progression On or After Platinum-Based ChemotherapyErin Larkins, Barbara Scepura, Gideon M Blumenthal, et al.
JAMA Oncology|October 16, 2015
Benefit-Risk Summary of Nivolumab for Patients With Metastatic Squamous Cell Lung Cancer After Platinum-Based Chemotherapy: A Report From the US Food and Drug AdministrationDickran Kazandjian, Sean Khozin, Gideon Blumenthal, et al.
JCO Oncology Practice|November 12, 2024
Administrative Aspects of Molecular Diagnostics-Oversight, Regulatory Approval Process, Clinical and Operational Workflows, and Payment ModelsLalan Wilfong, Lauren Baggett, Philip Reena, et al.
Cancer Discovery|December 2, 2022
Highlights of FDA Oncology Approvals in 2022: Tissue-Agnostic Indications, Dosage Optimization, and Diversity in Drug DevelopmentElizabeth S Duke, Michael J Fusco, Patrick DeMoss, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|April 2, 2022
US Food and Drug Administration Analysis of Patient-Reported Diarrhea and Its Impact on Function and Quality of Life in Patients Receiving Treatment for Breast CancerTing-Yu Chen, Bellinda L King-Kallimanis, Lyna Merzoug, et al.
Pageof 4